Core Insights - Galectin Therapeutics is advancing its NAVIGATE Phase 2b/3 trial of belapectin, targeting MASH associated liver cirrhosis and portal hypertension, with an interim analysis expected in December 2024 [2][3]. Company Overview - Galectin Therapeutics focuses on developing therapies for chronic liver disease and cancer, with its lead drug belapectin targeting galectin-3, a protein involved in inflammatory and fibrotic diseases [5]. Clinical Trial Progress - The NAVIGATE trial is evaluating the efficacy and safety of belapectin in 357 patients across 14 countries, with interim data readout anticipated in late December 2024 [3]. - Recent data presented at the EASL 2024 Congress indicated that collagen content in liver biopsies of MASH cirrhotic patients does not correlate with portal pressure, emphasizing the need for endoscopies in assessing disease progression [2][3]. Financial Highlights - As of June 30, 2024, the company had $25.6 million in cash and cash equivalents, with an additional $10 million available under a line of credit [4]. - Research and development expenses for Q2 2024 were $9.8 million, up from $7.4 million in Q2 2023, primarily due to the NAVIGATE trial [4]. - The net loss applicable to common stockholders for Q2 2024 was $12.4 million, or $0.20 per share, compared to a net loss of $9.2 million, or $0.15 per share, in Q2 2023 [4][8]. Balance Sheet Data - Total assets as of June 30, 2024, were $27.7 million, with total liabilities amounting to $109.8 million [9]. - The total stockholders' equity deficit was $83.9 million as of June 30, 2024 [9].

Core Viewpoint - Galectin Therapeutics has appointed Dr. Khurram Jamil as Chief Medical Officer, emphasizing his expertise in liver disease and leadership in the NAVIGATE clinical trial for belapectin, a drug targeting MASH cirrhosis [1][2][3]. Company Overview - Galectin Therapeutics focuses on developing novel therapies for chronic liver disease and cancer, with its lead drug belapectin targeting galectin-3, which is involved in inflammatory and fibrotic diseases [4]. - The company has received Fast Track designation from the U.S. FDA for belapectin, which is aimed at treating metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis [4]. Clinical Development - The NAVIGATE Phase 2b/3 trial is evaluating the efficacy and safety of belapectin for preventing esophageal varices in patients with cirrhosis due to MASH, with 357 patients randomized across 14 countries [3]. - Interim top-line data from the Phase 2b portion of the NAVIGATE trial is expected in December 2024 [3]. Leadership Transition - Dr. Khurram Jamil succeeds Dr. Pol Boudes as Chief Medical Officer, with the company expressing gratitude for Dr. Boudes' service [2].

NORCROSS, Ga., June 04, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will attend the EASL 2024 meeting and deliver a scientific presentation. The meeting will be held June 5-8, 2024, in Milan, Italy. "At this year's meeting we are again pleased to share important scientific information with the hepatology community. Through the knowledge captured from our belapectin program, we are adding knowledge on ...

NORCROSS, Ga., June 04, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will attend the EASL 2024 meeting and deliver a scientific presentation. The meeting will be held June 5-8, 2024, in Milan, Italy. "At this year's meeting we are again pleased to share important scientific information with the hepatology community. Through the knowledge captured from our belapectin program, we are adding knowledge on ...

NORCROSS, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended March 31, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said "This quarter we remained laser-focused on progressing the NAVIGATE Phase 2b/3 trial of belapectin, which has a Fast Track Designation from the U.S. Food & Drug Administ ...

Pol Boudes, M.D., Chief Medical Officer added, "We are deeply saddened by the recent passing of Dr. Stephen A. Harrison. Stephen was involved in the belapectin clinical program since its inception. As the coordinating investigator of NAVIGATE, he was also a driving force to change the way we are designing clinical research in cirrhotic patients. Most notably, Stephen championed the prevention of esophageal varices as a clinical outcome that is both less subjective and more closely related to real world clin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN THERAPEUTICS INC. Nevada 04-3562325 (State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.) Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 4960 Peach ...

Data and Safety Monitoring Board (DSMB) recommends the continuation, without modifications, of the adaptive Phase 2b/3 NAVIGATE study of belapectin in metabolic dysfunction-associated steatohepatitis (MASH) liver cirrhosisFifth positive recommendation further supports favorable tolerability and safety profile of belapectinInterim Phase 2b efficacy readout anticipated in Q4 2024 NORCROSS, Ga., April 09, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics ...

Galectin Therapeutics (NASDAQ:GALT) just reported results for the fourth quarter of 2023.Galectin Therapeutics reported earnings per share of -16 cents. This met the analyst estimate for EPS of -16 cents.The company did not report any revenue for the quarter.InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to ana ...

Exhibit 99.1 Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2023. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said "We have been focused on advancing our Metabolic Dysfunction-Associated ...